Vertex receives european chmp positive opinion for kalydeco (ivacaftor) for children and adolescents with cystic fibrosis

Receives european chmp positive opinion for kalydeco (ivacaftor) for children and adolescents with cystic fibrosis between the ages 6 months and 18 years with the r117h mutation in the cftr gene.european commission will now review chmp's positive opinion.
VRTX Ratings Summary
VRTX Quant Ranking